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Antibody  persistence  in  two  cohorts  of adults,  who  received  inactivated  hepatitis  A (HAV)  vaccine
(1440El.U;  HavrixTM; GSK  Vaccines)  according  to a  0–6 or 0–12  month  schedule  in 1992–1993, has  been
measured annually.  After  20  years,  >97%  of  the  subjects  in  both  studies  were  seropositive  for  anti-HAV
antibodies.  Geometric  mean  concentrations  in the  according-to-protocol  cohorts  were  312 mIU/ml  in
34/36  subjects  vaccinated  initially  at 0–6 months  (NCT00289757)  and 317  mIU/ml  in 85/86  subjects
vaccinated  at 0–12  months  (NCT00291876).  Over  the  whole  follow-up  period,  seven  subjects  (2  +  5,
respectively)  lost  circulating  anti-HAV  antibodies  but mounted  a  strong  response  after  HAV  boosternactivated hepatitis A vaccine
ong-term follow-up
athematical modelling
administration  (1440El.U).  Mathematical  modelling,  which  was  applied  to assess  true  persistence  at
Year  20  (accounting  for drop-outs  and missing  data),  and  to predict  longer-term  persistence  conﬁrmed
previous  estimates  that  seropositive  anti-HAV  levels  would  persist  in  ≥95%  vaccinees  at  Year  30  and
≥90%  at  Year  40.
ClinicalTrials.Gov  number:  NCT00289757/NCT00291876
© 2015  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Hepatitis A virus (HAV) is responsible for the most common
orm of acute viral hepatitis [1,2] manifested as approximately 1.4
illion clinical cases worldwide each year [3]. Nevertheless, HAVnfections can be prevented by immunization with inactivated hep-
titis A vaccines, such as HavrixTM (strain HM175; GSK, Belgium)
hich was ﬁrst launched in 1992 and is now widely available [4].
Abbreviations: ATP, according to protocol; CI, conﬁdence interval; ELISA,
nzyme-linked immunosorbent assay; GMC, geometric mean concentration; HAV,
epatitis A virus.
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inactivated hepatitis A vaccine either at 0, 6 months or 0, 12 months,
were started in 1992–1993; the subjects have been subsequently
followed up and long-term antibody persistence measured [5–7].
In the most recent publication describing the Year 17 time-point,
all subjects who were vaccinated at 0, 6 months and 96.7% sub-
jects vaccinated according to the 0, 12 month schedule remained
seropositive [7]. In support of the clinical ﬁndings, mathematical
modelling has predicted that detectable anti-HAV antibodies will
persist for 20–25 years [8–10]. In the most recent modelling analy-
sis, based on the serology data collected after 17 years of follow-up,
it was predicted that ≥95% and ≥90% of subjects would remain
seropositive after 30 and 40 years, respectively [11].
This brief report presents the serological data collected at the
Year 20 time point. As results were only available for returning sub-
jects, and as subjects who  became seronegative received a booster
HAV dose and were excluded from analysis after Year 17, mathe-
matical modelling was  applied to take into account all subjects who
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. Materials and methods
Two double-blind, randomized primary vaccination studies
tarted in 1992–1993, assessed the immunogenicity and safety
f different lots of inactivated hepatitis A vaccine (1440El.U),
dministered either at 0, 6 months or 0, 12 months to healthy
AV-naïve adults [5]. Subjects who completed primary vaccina-
ion were invited to participate in the long-term follow-up phase
NCT00289757/NCT00291876) [6] whereby annual blood samples
ere collected up to Year 20. Anti-HAV antibodies were assessed
sing an in-house enzyme-linked immunosorbent assay (ELISA)
ssay (seropositivity cut-off: ≥20 mIU/ml) during the ﬁrst 11 years
nd by a commercially available enzyme-linked immunoassay
Enzygost, Siemens Healthcare, Germany; seropositivity cut-off:
15 mIU/ml) from Year 11 onwards [6]. Full details of the immuno-
enicity and safety assessments are described elsewhere [5–7].
ubjects becoming seronegative (anti-HAV antibody concentration
15 mIU/ml) were eligible to receive a booster vaccine dose within
ne year of blood sampling and were subsequently excluded from
urther follow-up.
Both studies were approved by the Ethics Review Committee
f the Antwerp University Hospital and were conducted in accor-
ance with the Declaration of Helsinki and Good Clinical Practice
uidelines. Returning subjects provided written informed consent
t each follow-up time-point before any interventions were per-
ormed.
.1. Statistical analyses
The immunogenicity analyses were performed on the long-
erm according-to-protocol (LT-ATP) cohort and the long-term
otal cohort (LT-Total). All subjects belonging to the total cohort
n the primary study and returning at the annual time points at
ears 16–20 constituted the LT-Total cohort for that year. The LT-
TP cohort included all subjects from the ATP cohort in the primary
tudy who had not received any additional HAV vaccine or recorded
ig. 1. Subject disposition in LT and LT-ATP cohorts. *Seven subjects (two from the 0, 6 m
ooster  dose and were excluded from follow-up after Year 17. See references [6,7] for pre3 (2015) 5723–5727
an abnormal increase in anti-HAV antibody concentrations since
the previous time point [5–7]. An abnormal increase of anti-HAV
antibody levels was  deﬁned as either a 4-fold or 2-fold increase if
the previous anti-HAV level for that subject was <100 mIU/ml or
≥100 mIU/ml, respectively [7]. At each time point, seropositivity
rates and geometric mean concentrations (GMCs) on seropositive
subjects were calculated for anti-HAV antibodies with 95% conﬁ-
dence intervals (CI).
As lot-to-lot consistency was  demonstrated in both primary
studies, the immunogenicity results for the pooled groups have
been used throughout.
The statistical analyses were performed using the Statistical
Analysis Systems (SAS) version 9.2 (SAS Institute Inc., Cary, NC).
2.2. Mathematical modelling for long-term estimates
The populations included in the mathematical modelling were
selected from the original LT-cohort at study start (modelling LT-
cohort), as previously described by Hens et al. [11]. Exclusions from
the modelling LT cohort at start of follow-up were mainly to avoid
over-estimation of vaccine-induced immunity by suspected pre-
existing immunity; furthermore some participants were excluded
for not having received all vaccine doses in the primary study (see
Fig. 1).
A linear mixed model that included an indicator variable for the
Year 11 assay change was  used to predict seropositivity rates (cut-
off: ≥15 mIU/ml) at 30, 40 and 50 years after vaccination. The model
was ﬁtted using all available data for both studies. The Akaike Infor-
mation Criterion (AIC) was  used for model selection and goodness
of ﬁt was  assessed using the standard diagnostic tools for linear
mixed models.
For data analysis, a complete re-assessment of the optimal set
of change-points was  done, rather than re-applying those used in
the previously ﬁtted models [11]. Both one- and two-change-points
models were evaluated. For both studies, the best 10 two change-
point models yielded lower AIC-values than the best model with
onth and ﬁve from the 0, 12 month schedules) who became seronegative received
sentation of Year 15 and 17 follow-up results, respectively.
H. Theeten et al. / Vaccine 3
Fig. 2. Evolution of anti-HAV antibody GMCs over 20 years (Year 20 LT-ATP Cohort
for  Immunogenicity). The laboratory assay was changed at Year 11 from an in-house
enzyme-linked immunoassay to a commercially-available one. Re-testing of the
Year  11 samples with the new assay indicated that anti-HAV GMCs were slightly



































1table thereafter [6]. Anti-HAV seropositivity cut-offs: up to Year 11: ≥20 mIU/ml;
ear  12 to Year 20: ≥15 mIU/ml
 single change-point. Because the model with change points at 6
nd 24 months after the second dose was ranked second and ﬁrst
or the 0, 12 month schedule and 0, 6 month schedule, respectively,
hose change points were selected as the ﬁnal set.
Data were processed using Microsoft Excel and SAS procedures
IXED and NLMIXED, symmetrized (antibody levels were log 10-
ransformed) and the mean trend of the observed antibody levels
as represented as described by Hens et al. [11]. The coefﬁcient
f simple determination (R2) and D index of agreement were also
alculated [11].
. Results
.1. Immunogenicity in subjects returning at Year 20
At Year 20, 50 subjects who had received HAV vaccination at 0, 6
onths and 116 subjects who received the vaccine at 0, 12 months
eturned for follow-up, of whom 36 and 86 subjects, respectively,
onstituted the LT-ATP cohorts (Fig. 1). The mean age was  47.6 years
range: 37–59 years) and 50.5 years (range: 42–60 years) in the LT-
TP cohorts, respectively; 77.8% and 74.4% of subjects were female,
espectively, and all subjects were Caucasian. The study cohorts at
ach time point were comparable to the original cohorts in terms
f demographic characteristics and post-dose 2 anti-HAV antibody
oncentrations.
After 20 years, all subjects in the LT-ATP cohorts in both stud-
es were seropositive for anti-HAV antibodies. GMCs in the LT-ATP
ohorts at Year 20 were 312 mIU/ml (95%CI: 233.2–416.8) and
17 mIU/ml (95%CI: 247.4–407.1) in subjects vaccinated initially
t 0, 6 months and 0, 12 months, respectively. Following primary
accination, a steep decline in GMC  was observed in both studies
p to Month 24, after which it appeared to stabilize (Fig. 2).
During 20 years of follow-up, seven subjects (two from the 0, 6
onths and ﬁve from the 0, 12 months schedules) lost circulating
nti-HAV antibodies. All, except one, mounted a strong anamnes-
ic response following HAV booster administration (1440El.U). The
re-booster antibody concentration in the subject who became
eronegative in the current time period was 16 mIU/ml, which rose
o 4894 mIU/ml on Day 30 post-booster. This subject reported grade
 pain on the day of vaccination and the following day.3 (2015) 5723–5727 5725
3.2. Modelling results (modelling LT-cohort)
A total of 281 subjects were included in the modelling analysis
(0, 6 month schedule: 173 and 0, 12 month schedule: 108 [11]);
of whom 22 and 17 participants, respectively had data excluded
from the analysis from a speciﬁc visit onwards due to: booster dose
received within/outside the study (7 and 4, respectively); abnormal
rise in consecutive measurements after dose 2 (12 and 12, respec-
tively); obvious outlier in observations (3 and 1, respectively).
Using ≥15 mIU/ml as the seropositivity cut-off value, these
model predictions corroborate the existing claim [11] that ≥95%
subjects will remain seropositive at Year 25 in both studies. The
seropositivity rates are estimated to remain consistently ≥90% up
to Year 40 after which they are expected to decline but remain
≥85% for both studies with 88.9% (78.7–95.3%) at Year 45 and
86.1% (75.9–93.5%) at Year 50 for the 0, 6 month schedule and
93.1% (83.8–95.9%) and 89.6% (80.3–92.5%), respectively for the 0,
12 month schedule (Fig. 3).
4. Discussion
The current studies are unique in terms of assessing the long-
term immune response to inactivated HAV vaccine for 20 years.
Indeed, the vaccine induced high levels of immunogenicity in both
studies and detectable anti-HAV antibodies persisted up to 20 years
in more than 97% of subjects. Following primary vaccination, a steep
decline in GMC  was observed in both studies up to Month 24, after
which the GMC  appeared to stabilize. Although our data suggest
that a 0–12 month schedule would induce higher antibody levels
resulting in higher predicted long-term antibody levels than a 0–6
month schedule, it should be noted that the study populations were
recruited independently. This observation may therefore also relate
to differences in known confounders such as age, gender or BMI.
Our ﬁrst modelled estimation of long-term persistence, based
on extrapolating the linear trend in 5 years of observed data, was
that circulating antibodies would last on average 20–25 years after
the second vaccine dose [10]. Using linear mixed models on 6–10
years of observed data, we concluded that circulating antibodies
would persist in ≥95% of the vaccinees at year 25 [4]. Our current
results, observed 20 years after vaccination, conﬁrm that the vast
majority of subjects still present circulating antibodies at that time-
point, and suggest that the long-term decline in GMC  seems to have
levelled off. However, whether a true plateau in GMCs has been
achieved remains to be conﬁrmed. Indeed, Wiedermann et al. in
their 7-year follow-up study of subjects vaccinated at 0, 1–2 and
12 months, reported the initial steep decline followed by a second
slower reduction in anti-HAV antibodies, whereby seroprotective
persistence was estimated to vary between 24 and 47 years [12].
Nevertheless, our results are consistent with other studies of long-
term anti-HAV persistence in adults [13–15] and children [14,16].
Seven seronegative subjects who received additional vaccine as
part of the study [6,7] were excluded from follow-up after Year 17,
which could have potentially biased the persistence rates upwards.
To overcome these limitations, a mathematical model was  applied
to assess true persistence at Year 20, whereby the statistical anal-
ysis took into account all available test results since the study start
from all subjects who received the full vaccination course irre-
spective of their anti-HAV antibody serostatus, up until they were
eliminated for any reason. The modelling results corroborate the
previous estimates made up to Year 40 [11] and suggest that per-
sistence extends beyond that time-point.
As well as being unique amongst clinical trials for such pro-
longed follow-up, these studies have allowed us to compare actual
long-term clinical results with early model predictions. Inactivated
HAV vaccine confers a high level of seroprotection against HAV for
at least 20 years and current modelling predicts that seropositive
5726 H. Theeten et al. / Vaccine 33 (2015) 5723–5727
Fig. 3. Observed individual proﬁles and population-averaged estimation of anti-HAV levels using all available test results and a model with linear time trend (modelling LT









ipanel  A) and 0, 12 month schedule (panel B). Black lines show the observed indivi
evels.
nti-HAV levels will persist in ≥95% vaccinees at Year 30, and ≥90%
t Year 40.
Havrix is a trademark of the GSK group of companies.
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ppendix. Model description and parameters
We  used a linear mixed model with two change points (6 and 24
onths) after the second dose, without additional covariates. The
odel was applied on all available data from Year 1 to Year 20. The
ollowing model structure and parameters were used:
og10(titreij) = (ˇ0 + ˇ1Inewtest,j + b0i) + (ˇ2 + b2i)timeij
+ (ˇ3 + b3i)(timeij − cp1)+ + (ˇ4 + ˇ5Inewtest,j
+ b4i)(timeij − cp2)+ + ∈ij,
ith log10(titreij), the basis 10 log antibody level of subject i at time
; time in months after the second dose; cpi, i = 1, 2 the two change-
oints, (. . .)+ the heavisde function taking value 0 if the argument
s negative and value 1 if the argument is positive, and Inewtest the
ndicator function rendering value 1 if the new test is used and 0
therwise. Whereas the  ˇ parameters represent ﬁxed effects, the
 parameters represent random effects and ∈ij ∼ N(0, 2) represent
he independent and normally distributed error terms.
[
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